1281292 - 11759070 - 1

11 Oversold NASDAQ Stocks To Buy Right Now

Published on March 13, 2024 at 3:32 pm by Fatima Farooq in Hedge Funds, News

In this article, we will be taking a look at 11 oversold NASDAQ stocks to buy right now. To skip our detailed analysis of current stock market news, you can go directly to see the 5 Oversold NASDAQ Stocks To Buy Right Now.

NASDAQ Leads The Market

On March 12, the Nasdaq Composite Index was up by 1.5%, spearheaded by the technology stocks that have been leading the tech-heavy index ever higher for a long time now. While being heavily focused on the tech sector, the NASDAQ is also known for its exposure to other sectors, such as the consumer discretionary, healthcare, and financial sectors, all of which contribute to the index’s success. As a result of these market leaders, the NASDAQ has steadily become an attractive marketplace for budding and seasoned investors alike.

Many investors today are thinking about current market dynamics in terms of the future outlook for the upcoming months and what that may mean for investors. On March 12, Gabriela Santos, chief market strategist at JPMorgan, joined CNBC’s “Closing Bell” to discuss her thoughts on the current outlook and market. Here’s what she had to say:

“We do sound positive, first on the fundamentals. For the economy, we see growth normalizing this year 2%, but zero recession in our base case. We see inflation also moderating towards 2% by the end of the year, so you still have a pretty resilient nominal growth backdrop for companies, so resilient revenue growth. At the same time, it seem to us that the big takeaway from fourth-quarter earnings was a bottoming in the margin contraction from last year.”

The highlights above show that a positive trend for stocks should continue as we move forward into 2024, which should be encouraging for investors looking to buy into the market. Considering the upside gains in the NASDAQ being seen so far, this index may be a good place to start for those looking to buy. This is especially the case considering the fact that the index compromises of some of the most influential and profitable names in the market right now, most notably NVIDIA Corporation (NASDAQ:NVDA), Apple Inc. (NASDAQ:AAPL), and Amazon.com, Inc. (NASDAQ:AMZN).

Diversifying Outside of Tech in 2024

For investors, one thing to note at present is that big tech isn’t the only area to keep an eye on when it comes to the Nasdaq Composite Index. Santos, on CNBC’s “Closing Bell,” highlights the fact that several other names within the tech sector and outside of it are now also beginning to rake in the gains. Here’s what she said:

“It’s actually a healthy sign. For example, within mega-cap tech, the ‘Magnificent Seven’ that dominated so much of returns last year, there was dispersion within the group but they were all up. This year, you’re seeing quite substantial dispersion within the group. Some are up double digits, some are performing in line with the market, and some are down double digits. That’s very healthy to see, thinking of the actual companies as individuals. You’re also seeing other parts of the tech sector participate, and other sectors. Things like healthcare, which we had talked a lot about last year as being one of our favorite sectors, contributing as well. So I think it’s a very healthy appreciation, that it’s not just AI, it’s not just about the initial beneficiaries of that theme, it’s also about resilient earnings.”

In light of the above, we believe that while tech is definitely an area to keep track of this year, investors should not just put all their eggs in the tech basket. As such, we have compiled a list of oversold stocks listed on the NASDAQ to buy right now. Our list compromises both oversold stocks in the tech sector and in other sectors, such as healthcare, to give a more holistic set of options to investors looking to buy right now. You’ll thus find that we have quite a few options below to choose from, ranging from cheap healthcare stocks to buy to oversold tech stocks to buy.

A trader in a financial institution using fundamentals analysis to select stocks for a portfolio.

Our Methodology

We used the Relative Strength Index (RSI) indicator to pick oversold stocks listed on the Nasdaq Composite Index for our list. The RSI indicator is a momentum indicator used in the technical analysis of stocks by measuring the speed and magnitude of a security’s recent price changes to evaluate whether the price of that security is overvalued or undervalued. Stocks with RSI values of over 70 are traditionally considered overbought, while those with RSI values under 30 are oversold. We thus used a stock screener to find oversold stocks listed on the NASDAQ with RSI values under 30 and then ranked them based on this metric, from the highest to the lowest RSI value. We also mentioned the number of hedge funds holding stakes in each stock, using Insider Monkey’s hedge fund data for the fourth quarter. Hedge funds’ top 10 consensus stock picks outperformed the S&P 500 Index by over 140 percentage points over the last 10 years (see the details here). That’s why we pay very close attention to this often-ignored indicator.

Oversold NASDAQ Stocks To Buy Right Now

11. Axsome Therapeutics, Inc. (NASDAQ:AXSM)

Number of Hedge Fund Holders: 31

14-day RSI as of March 13: 29.58

Based in New York, Axsome Therapeutics, Inc. (NASDAQ:AXSM) is a pharmaceutical company. It develops novel therapies for central nervous system disorders in the US.

A Buy rating and a $180 price target were reiterated on Axsome Therapeutics, Inc. (NASDAQ:AXSM) on March 4 by analysts at HC Wainwright & Co.

There were 31 hedge funds long Axsome Therapeutics, Inc. (NASDAQ:AXSM) in the fourth quarter, with a total stake value of $968.4 million.

Biotechnology Value Fund / BVF Inc was the most prominent shareholder in Axsome Therapeutics, Inc. (NASDAQ:AXSM) at the end of the fourth quarter, holding 1.9 million shares in the company.

While Axsome Therapeutics, Inc. (NASDAQ:AXSM) is on our list of oversold stocks, it has the potential to be a great NASDAQ stock, like NVIDIA Corporation (NASDAQ:NVDA), Apple Inc. (NASDAQ:AAPL), and Amazon.com, Inc. (NASDAQ:AMZN).

10. Pacific Biosciences of California (NASDAQ:PACB)

Number of Hedge Fund Holders: 28

14-day RSI as of March 13: 29.54

On February 16, analysts at UBS maintained a Buy rating and a $12 price target on Pacific Biosciences of California (NASDAQ:PACB).

Pacific Biosciences of California (NASDAQ:PACB) is a life sciences tools and services company based in Menlo Park, California. The company designs, develops, and manufactures sequencing solutions to resolve genetically complex problems.

A total of 28 hedge funds were long Pacific Biosciences of California (NASDAQ:PACB) in the fourth quarter, with a total stake value of $646 million.

ARK Investment Management was the largest shareholder in Pacific Biosciences of California (NASDAQ:PACB) at the end of the fourth quarter, holding 34.5 million shares in the company.

9. Aurora Innovation Inc. (NASDAQ:AUR)

Number of Hedge Fund Holders: 16

14-day RSI as of March 13: 28.99

Aurora Innovation Inc. (NASDAQ:AUR) was spotted in the 13F holdings of 16 hedge funds at the end of the fourth quarter, with a total stake value of $160.7 million.

Aurora Innovation Inc. (NASDAQ:AUR) is an application software company based in Pittsburgh, Pennsylvania. The company develops the Aurora Driver platform, which combines a suite of self-driving hardware, software, and data services to adapt and interoperate vehicles.

8. Seres Therapeutics, Inc. (NASDAQ:MCRB)

Number of Hedge Fund Holders: 20

14-day RSI as of March 13: 28.92

Seres Therapeutics, Inc. (NASDAQ:MCRB) is a biotechnology company based in Cambridge, Massachusetts on our list of oversold stocks to buy right now. The company develops a novel class of biological drugs designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.

We saw 20 hedge funds long Seres Therapeutics, Inc. (NASDAQ:MCRB) in the fourth quarter, with a total stake value of $22.3 million.

Oppenheimer analysts reiterated an Outperform rating and a $5 price target on Seres Therapeutics, Inc. (NASDAQ:MCRB) on March 6.

7. Digital Turbine, Inc. (NASDAQ:APPS)

Number of Hedge Fund Holders: 19

14-day RSI as of March 13: 28.14

D E Shaw was the largest shareholder in Digital Turbine, Inc. (NASDAQ:APPS) at the end of the fourth quarter, holding 1.9 million shares in the company.

Based in Austin, Texas, Digital Turbine, Inc. (NASDAQ:APPS) is another application software company on our list of oversold stocks to buy right now. The company operates a mobile growth platform for advertisers, publishers, carriers, and device original equipment manufacturers.

Digital Turbine, Inc. (NASDAQ:APPS) was spotted in the portfolios of 19 hedge funds in the fourth quarter, with a total stake value of $56.4 million.

A Neutral rating and a $4.5 price target were maintained on Digital Turbine, Inc. (NASDAQ:APPS) on February 8 by Roth MKM analysts.

Greenhaven Road Capital mentioned Digital Turbine, Inc. (NASDAQ:APPS) in its second-quarter 2023 investor letter:

“It is an understatement to say that the past year-plus has been frustrating for Digital Turbine, Inc. (NASDAQ:APPS) shareholders (us). It has become a smaller position through price declines and sales of shares as uncertainty increased on both the potential for new initiatives as well as their timing.

I often reflect on what went wrong. How did this go from a growth stock to a value stock? There have been two causes, in my opinion. The first is that their product delivering content (not apps) on phones lost T-Mobile as a customer – sometimes we are one day closer to a bad outcome: the loss of a customer. The second, and bigger issue was with their SingleTap product. SingleTap is a technology that “enables smartphone users to instantly install an app to their Android device with a single tap…bypassing the noise of the app store environment, and dramatically increasing conversions.” The higher conversion rates mean lower costs per app install or app opening…” (Click here to read the full text)

6. Caribou Biosciences Inc. (NASDAQ:CRBU)

Number of Hedge Fund Holders: 23

14-day RSI as of March 13: 28.13

At the end of the fourth quarter, 23 hedge funds were long Caribou Biosciences Inc. (NASDAQ:CRBU), with a total stake value of $146.9 million.

On March 12, analysts at RBC Capital maintained an Outperform rating and a $19 price target on Caribou Biosciences Inc. (NASDAQ:CRBU).

Based in Berkeley, California, Caribou Biosciences Inc. (NASDAQ:CRBU) is another biotech company on our list of oversold stocks. It engages in developing genome-edited allogeneic cell therapies to treat hematologic malignancies in the US and internationally.

Caribou Biosciences Inc. (NASDAQ:CRBU) is a name on our list of oversold stocks that is highly popular among hedge funds today, just like NVIDIA Corporation (NASDAQ:NVDA), Apple Inc. (NASDAQ:AAPL), and Amazon.com, Inc. (NASDAQ:AMZN).

Click to continue reading and see the 5 Oversold NASDAQ Stocks To Buy Right Now.

The $250 Trillion AI Hype is Real. A few years from now, you’ll probably wish you’d bought this stock.

Published on May 16, 2026 at by Inan Dogan, PhD

Dr. Ian Dogan

Co-Founder and Research Director at Insider Monkey

When Jeff Bezos said that one breakthrough technology would shape Amazon’s destiny, even Wall Street’s biggest analysts were caught off guard.

Fast forward a year and Amazon’s new CEO Andy Jassy described generative AI as a “once-in-a-lifetime” technology that is already being used across Amazon to reinvent customer experiences.

At the 8th Future Investment Initiative conference, Elon Musk predicted that by 2040 there would be at least 10 billion humanoid robots, with each priced between $20,000 and $25,000.

Do the math. According to Musk, this technology could be worth $250 trillion by 2040.

Put another way, that’s roughly equal to:

175 Teslas
107 Amazons
140 Metas
84 Googles
65 Microsofts
And 55 Nvidias

And here’s the wild part — this $250 trillion wave isn’t tied to one company, but to an entire ecosystem of AI innovators set to reshape the global economy.

It’s a leap so massive, it could reshape how businesses, governments, and consumers operate worldwide.

Even if that $250 trillion figure sounds ambitious, major firms like PwC and McKinsey still see AI unlocking multi-trillion-dollar potential.

How could anything be worth that much?

The answer lies in a breakthrough so powerful it’s redefining how humanity works, learns, and creates.

And this breakthrough has already set off a frenzy among hedge funds and Wall Street’s top investors.

What most investors don’t realize is that one under-owned company holds the key to this $250 trillion revolution.

In fact, Verge argues this company’s supercheap AI technology should concern rivals.

Before I reveal the details, let’s talk about how some of the richest people on the planet are positioning themselves.

Bill Gates sees artificial intelligence as the “biggest technological advance in my lifetime,” more transformative than the internet or personal computer, capable of improving healthcare, education, and addressing climate change.
Larry Ellison — through Oracle, is spending billions on Nvidia chips and partnering with Cohere to embed generative AI across Oracle’s cloud and apps.
Warren Buffett — not known for tech hype — says this breakthrough could have a ‘hugely beneficial social impact.

When billionaires from Silicon Valley to Wall Street line up behind the same idea — you know it’s worth paying attention to.

Even as we admire what Tesla, Nvidia, Alphabet, and Microsoft have built, we believe an even greater opportunity lies elsewhere…

But the real story isn’t Nvidia — it’s a much smaller company quietly improving the critical technology that makes this entire revolution possible.

And judging by what I’m hearing from both Silicon Valley insiders and Wall Street veterans…

This prediction might not be bold at all:

A few years from now, you’ll wish you’d owned this stock.

The best part? You can discover everything about this company and its groundbreaking technology right now.

I’ve compiled everything you need to know about this groundbreaking company in a detailed, members-only report.

Trust me — you’ll want to read this report before putting another dollar into any tech stock.

For a ridiculously low price of just $9.99 a month, you can unlock a year’s worth of in-depth investment research and exclusive insights – that’s less than a single fast food meal!

Here’s why this is a deal you can’t afford to pass up:

• Access to our Detailed Report on this Game-Changing AI Stock: Our in-depth report dives deep into our #1 AI stock’s groundbreaking technology and massive growth potential.

• 11 New Issues of Our Premium Readership Newsletter: You will also receive 11 new issues and at least one new stock pick per month from our monthly newsletter’s portfolio over the next 12 months. These stocks are handpicked by our research director, Dr. Inan Dogan.

• One free upcoming issue of our 70+ page Quarterly Newsletter: A value of $149

• Bonus Reports: Premium access to members-only fund manager video interviews

• Ad-Free Browsing: Enjoy a year of investment research free from distracting banner and pop-up ads, allowing you to focus on uncovering the next big opportunity.

• 30-Day Money-Back Guarantee: If you’re not absolutely satisfied with our service, we’ll provide a full refund within 30 days, no questions asked.

If you’re thinking about getting in, don’t wait – because once Wall Street catches wind of this story, the easy money will be gone.

Space is Limited! Only 1000 spots are available for this exclusive offer. Don’t let this chance slip away – subscribe to our Premium Readership Newsletter today and unlock the potential for a life-changing investment.

Here’s what to do next:

1. Subscribe to our Premium Readership Newsletter for just $9.99 a month. (33% Off – was $14.99).

2. Enjoy a year of ad-free browsing, exclusive access to our in-depth report on the revolutionary AI company, and the upcoming issues of our Premium Readership Newsletter over the next 12 months.

3. Sit back, relax, and know that you’re backed by our ironclad 30-day money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!

Insider Monkey Ads

Buy This $3 Stock Now Before the 400% Surge Begins

Published on May 15, 2026 at by Inan Dogan, PhD

Dr. Ian Dogan

Co-Founder and Research Director at Insider Monkey

My name is Inan Dogan. I’m the co-founder and Research Director of Insider Monkey. I have an important message for you today.

Since March 2017, my stock picks have returned 16.5% annually. Today, I’ve found an opportunity even bigger than my British American Tobacco call.

Two years ago, Wall Street wrote off British American Tobacco (BTI) as a “melting ice cube.” The stock had crashed 40% from its peak, and consensus said the business was dying.

We looked under the cover and realized they were wrong.

We alerted our subscribers, and BTI returned 90% in just 16 months.

Now if you had invested just $10,000 in BTI in June 2024, you’d be sitting on $19,000 in October 2025.

Today, we have identified a nearly identical pattern in a digital-first giant trading at $3.

While the market panics over a surface-level revenue decline, our PhD-led research shows management has actually surgically cut $100 million in waste to focus on high-margin growth.

This pattern is a hallmark of our 16.5% annual return track record. The current opportunity offers a 400% upside potential—dwarfing even our 90% BTI return.

Get the ticker for our new “Underdog” pick and the full BTI case study for just 99 cents.

This exclusive offer is for NEW newsletter subscribers ONLY! Join our Premium Readership Newsletter for only $0.99 and become part of a savvy investor community.!

This offer vanishes in 7 days, so don’t miss your chance to lock in market beating returns! Sign up NOW! The monthly newsletter comes with a 30-day, no-risk money-back guarantee. This offer is available to the first 1000 new investors who respond.

Here’s why this is a deal you can’t afford to pass up:

Access to our Detailed Report on this $3 stock with 400% upside potential.
BONUS REPORT on our #1 AI-Robotics Stock with 10000% upside potential: Our in-depth report dives deep into our #1 AI/robotics stock’s groundbreaking technology and massive growth potential.
One New Issue of Our Premium Readership Newsletter: You will also receive one new issue per month and at least one new stock pick per month from our monthly newsletter’s portfolio over the next 12 months. These stocks are handpicked by our research director, Dr. Inan Dogan.
One free upcoming issue of our 70+ page Quarterly Newsletter: A value of $149
Bonus Content: Premium access to members-only fund manager video interviews
Ad-Free Browsing: Enjoy a month of investment research free from distracting banner and pop-up ads, allowing you to focus on uncovering the next big opportunity.
Lifetime Price Guarantee: Your renewal rate will always remain the same as long as your subscription is active.
30-Day Money-Back Guarantee: If you’re not absolutely satisfied with our service, we’ll provide a full refund within 30 days, no questions asked.

Here’s what to do next:

1. Head over to our website and subscribe to our Premium Readership Newsletter for just $0.99.

2. Enjoy a month of ad-free browsing, exclusive access to our in-depth report on the Trump tariff and nuclear energy company as well as the revolutionary AI-robotics company, and the upcoming issues of our Premium Readership Newsletter.

3. Sit back, relax, and know that you’re backed by our ironclad 30-day money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!

Markets

Insider Trading

Hedge Funds

Retirement

Opinion

Log In

Sign Up

11 Oversold NASDAQ Stocks To Buy Right Now

Published on March 13, 2024 at 3:32 pm by Fatima Farooq in Hedge Funds, News

NASDAQ Leads The Market

Diversifying Outside of Tech in 2024

Oversold NASDAQ Stocks To Buy Right Now

11. Axsome Therapeutics, Inc. (NASDAQ:AXSM)

10. Pacific Biosciences of California (NASDAQ:PACB)

9. Aurora Innovation Inc. (NASDAQ:AUR)

8. Seres Therapeutics, Inc. (NASDAQ:MCRB)

7. Digital Turbine, Inc. (NASDAQ:APPS)

6. Caribou Biosciences Inc. (NASDAQ:CRBU)

The $250 Trillion AI Hype is Real. A few years from now, you’ll probably wish you’d bought this stock.

Published on May 16, 2026 at by Inan Dogan, PhD

Here’s why this is a deal you can’t afford to pass up:

Buy This $3 Stock Now Before the 400% Surge Begins

Published on May 15, 2026 at by Inan Dogan, PhD

Here’s why this is a deal you can’t afford to pass up:

Markets

Insider Trading

Hedge Funds

Retirement

Opinion

Premium

Log In

Sign Up

11 Oversold NASDAQ Stocks To Buy Right Now

Published on March 13, 2024 at 3:32 pm by Fatima Farooq in Hedge Funds, News

Share

NASDAQ Leads The Market

Diversifying Outside of Tech in 2024

Oversold NASDAQ Stocks To Buy Right Now

11. Axsome Therapeutics, Inc. (NASDAQ:AXSM)

10. Pacific Biosciences of California (NASDAQ:PACB)

9. Aurora Innovation Inc. (NASDAQ:AUR)

8. Seres Therapeutics, Inc. (NASDAQ:MCRB)

7. Digital Turbine, Inc. (NASDAQ:APPS)

6. Caribou Biosciences Inc. (NASDAQ:CRBU)

Share

The $250 Trillion AI Hype is Real. A few years from now, you’ll probably wish you’d bought this stock.

Published on May 16, 2026 at by Inan Dogan, PhD

Here’s why this is a deal you can’t afford to pass up:

Buy This $3 Stock Now Before the 400% Surge Begins

Published on May 15, 2026 at by Inan Dogan, PhD

Here’s why this is a deal you can’t afford to pass up: